FDA noted that a part of a vessel used to produce Ethinylestradiol API was not maintained in a clean condition, even though it was in contact with the product. The agency requested a copy of the revised SOP after it has been approved.Īnother violation listed in the Warning Letter was Bayer’s failure to establish and follow procedures for maintaining and cleaning equipment. FDA said Bayer’s revised draft SOP appeared adequate.
In its response, Bayer said it was revising its standard operating procedure (SOP) for handling OOS results to stress the importance of conducting and documenting OOS investigations. When OOS investigations were performed, they did not adequately determine root causes or provide for corrective action, said FDA. For example, during release and stability testing of APIs, individual OOS assay results were disregarded, and no OOS investigations were performed after OOS results were obtained. The company did not conduct adequate investigations that included scientific justification to support conclusions and suggested appropriate corrective actions. In addition, Bayer’s quality unit failed to maintain authority and responsibility to review and conduct investigations, according to the Warning Letter. Sample results should be treated independently, said FDA, and an OOS result should not be averaged with a passing individual result. FDA also disagreed with Bayer’s interpretation of the agency’s OOS guidance. In the Warning Letter, FDA said it disagreed with Bayer’s conclusions and noted that “an assay test is used to determine potency, not method variability.” The results were true OOS values, and the batches should not have been released, according to the agency. Bayer also concluded that the OOS results were within the accepted variation of the analytical method and that the quality of the batches in question was not affected. In all cases, Bayer concluded that no analytical errors had been identified and that the values were true OOS results. The company found nine instances in which OOS results and passing results were averaged together. The company approved API batches for release to the US market based on passing, averaged assay results.īayer’s response to FDA described a retrospective investigation that it had conducted of all API batches released to the US market between 20. In its Warning Letter, FDA acknowledged that some corrections “appear to have been completed or will soon be implemented,” but said that Bayer’s response did not adequately address some deficiencies.įDA noted that Bayer had established procedures that allow for the averaging of out-of-specification (OOS) and within-specification analytical test results from separate samples. 2–10, 2009 and was recently posted on the agency’s website.īayer received a Form 483 at the end of the inspection and sent a written response to FDA on Apr. The letter follows FDA’s inspection of Bayer’s Bergkamen, Germany, API plant on Mar. 5, 2009, citing deviations from current good manufacturing practice in the manufacture of nonsterile active pharmaceutical ingredients (APIs).
#SCHERING BAYER FULL#
Compare Standard and Premium Digital here.Īny changes made can be done at any time and will become effective at the end of the trial period, allowing you to retain full access for 4 weeks, even if you downgrade or cancel.The US Food and Drug Administration sent Bayer Schering Pharma (Berlin) a Warning Letter on Aug. You may also opt to downgrade to Standard Digital, a robust journalistic offering that fulfils many user’s needs.
If you’d like to retain your premium access and save 20%, you can opt to pay annually at the end of the trial. If you do nothing, you will be auto-enrolled in our premium digital monthly subscription plan and retain complete access for $69 per month.įor cost savings, you can change your plan at any time online in the “Settings & Account” section. For a full comparison of Standard and Premium Digital, click here.Ĭhange the plan you will roll onto at any time during your trial by visiting the “Settings & Account” section. Premium Digital includes access to our premier business column, Lex, as well as 15 curated newsletters covering key business themes with original, in-depth reporting. Standard Digital includes access to a wealth of global news, analysis and expert opinion.
During your trial you will have complete digital access to FT.com with everything in both of our Standard Digital and Premium Digital packages.
0 kommentar(er)
